Download the ICS Branding Pack
Podium Short Oral Session 10 Neurourology and Interventions 206 Investigating the risk of bladder cancer in patients with Neurogenic Lower Tract Dysfunction (NLUTD): prevalence of DNA methylation of a panel of genes in patients’ urine
Podium Short Oral Session 15 Health Services and Community Care 264 Health Behaviours, Quality of Life and Treatment Adherence in neurogenic versus non-neurogenic Urinary Incontinence
Podium Short Oral Session 3 Novel Techniques and Approaches in Basic Science 30 The effect of Low Intensity shockwave treatment on the bladder of a diabetic rat model
Open Discussion ePoster Session 18 E-Poster 2 342 Can we identify prognostic factors for successful outcome of pelvic floor muscle training in female urinary incontinence?
Open Discussion ePoster Session 19 Open Discussion ePosters 2 370 Can we predict a diagnosis of detrusor underactivity (DUA) or bladder outlet obstruction in women by non-invasive parameters?
Open Discussion ePoster Session 7 Open Discussion ePosters 120 Parallel study of molecular changes in the prostate and bladder of men with benign prostate enlargement (BPE) and overactive bladder (OAB) symptoms and in comparison with controls
Podium Express Session 13 Rapid Communications in Urology 227 Prognostic factors for changes of erectile function before and after treatment in sleep apnea patients: is there a role for nocturia? A controlled study
Podium Short Oral Session 4 Male Lower Urinary Tract Symptoms - Should We Treat Only the Prostate? 40 Combination of solifenacin with tamsulosin but not tamsulosin affects morphometric and functional parameters of the prostate in patients with benign prostate enlargement (BPE) and overactive bladder (OAB). Results from a randomized pilot study.
Non Discussion Abstract Session 32 Non Discussion Abstracts 797 Do alpha-blockers exert their effect via the prostate, the bladder or both? A study of post-tamsulosin changes in the prostate and bladder of men with benign prostate enlargement (BPE) and overactive bladder (OAB) symptoms.
Non Discussion Poster Session 34 339 Changes in the spinal expression of receptors involved in the control of the lower urinary tract following intradetrusor Botulinum neurotoxin A (BoNT/A) injections: results from normal rats
Non Discussion Poster Session 34 443 Does the use of incontinence protection affect women’s sexual function and self-image? Preliminary results of a prospective observational controlled study in peri- or post-menopausal women with predominantly urgency incontinence
Non Discussion Poster Session 34 445 Is there a role for training of the transversus abdominis muscles in the physiotherapy schemes applied in the treatment of female urinary incontinence?
Non Discussion Poster Session 34 518 Do patients with neurogenic lower urinary tract dysfunction (NLUTD) benefit from treatment with alpha-blockers? A retrospective study of men and women with multiple sclerosis (MS) and mixed LUTS
Non Discussion Poster Session 34 590 Factors affecting the agreement between clinical and urodynamic diagnosis in male patients with resistant to medical treatment LUTS: focus on self-reported quality of life impairment
Podium Poster Session 22 Imaging and the Brain 225 Real-time ultrasonographic evaluation of the levator ani and transversus abdominis muscles: is there a role in female urinary incontinence?
Podium Poster Session 4 Neurourology 34 Do cannabinoid agonists used for the treatment of refractory lower urinary tract symptoms in patients with neurogenic detrusor overactivity have an effect on bladder afferent pathways?
Non Discussion Poster Session 29 358 The burden of incontinence in association with LUTS and sexual function: a questionnaire-based survey on treatment seeking and expectations
Non Discussion Poster Session 29 370 Do psychosocial factors affect the way people with similar severity of lower urinary tract symptoms (LUTS) perceive bother and seek medical advice?
Non Discussion Abstract Session 31 Read by Title 698 Is there agreement between physicians’ diagnoses and operator-independent assessment tools in women with voiding symptoms?
Non Discussion Poster Session 19 279 Screening for Lower Urinary Tract Symptoms (LUTS) in Diabetic Men: questionnaire-based prevalence and associations with health, sexual function and quality of life aspects
Podium Poster Session 12 Clinical Neurourology 97 RECOMMENDATIONS ON THE USE OF BOTULINUM TOXIN IN THE TREATMENT OF LOWER URINARY TRACT (LUT) DISORDERS AND PELVIC FLOOR DYSFUNCTIONS: A EUROPEAN CONSENSUS PANEL REPORT
Non Discussion Abstract Session 19 Read By Title 323 Prevalence, bother and treatment seeking behaviour related to urinary incontinence, LUTS and sexual dysfunction in a general hospital’s inpatient population: Results from the Hospitalised and Outpatients’ Profile and Expectations Study (HOPES)
Non Discussion Abstract Session 19 Read By Title 356 Medical and psychosocial factors determining bother and treatment seeking behaviour related to urinary incontinence: Results from the Hospitalized and Outpatients’ Profile and Expectations Study (HOPES)
Non Discussion Abstract Session 19 Read By Title 372 Factors predicting bother and treatment seeking behaviour related to lower urinary tract symptoms (LUTS): Results from the Hospitalized and Outpatients’ Profile and Expectations Study (HOPES)
Dr Apostolos Apostolidis declared on the Thursday 7th July 2016 that they had the following existing or known future financial relationships or affiliations:
Scientific Committee Member